Based on the Penumbra Inc stock forecast from 14 analysts, the average analyst target price for Penumbra Inc is USD 281.88 over the next 12 months. Penumbra Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Penumbra Inc is Neutral, which is based on 6 positive signals and 7 negative signals. At the last closing, Penumbra Inc’s stock price was USD 272.32. Penumbra Inc’s stock price has changed by +3.83% over the past week, +4.49% over the past month and +25.23% over the last year.
No recent analyst target price found for Penumbra Inc
No recent average analyst rating found for Penumbra Inc
Company Overview Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California. Read Less
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Li...Read More
Frequently Asked Questions About Penumbra Inc (PEN) Stock
Based on ratings from 14 analysts Penumbra Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 20 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on PEN's stock to indicate if its a good dividend stock.
Based on targets from 14 analysts, the average taret price for PEN is USD 281.88 over the next 12 months. The maximum analyst target price is USD 340 while the minimum anlayst target price is USD 150.
PEN stock's Price/Earning ratio is 778.91.
Our analysis grades PEN stock's Price / Earning ratio at F. This means that PEN stock's Price/Earning ratio is above 95% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this PEN may be a overvalued for its sector.
The last closing price of PEN's stock was USD 272.32.
The most recent market capitalization for PEN is USD 10.50B.
Based on targets from 14 analysts, the average taret price for PEN is projected at USD 281.88 over the next 12 months.
This means that PEN's stock price may go up by +3.51% over the next 12 months.
We can't find any ETFs which contains Penumbra Inc's stock.
As per our most recent records Penumbra Inc has 4,500 Employees.
Penumbra Inc's registered address is One Penumbra Place, Alameda, CA, United States, 94502.
You can get more information about it from Penumbra Inc's website at https://www.penumbrainc.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Penumbra Inc (PEN) Stock
Based on ratings from 14 analysts Penumbra Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 20 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on PEN's stock to indicate if its a good dividend stock.
Based on targets from 14 analysts, the average taret price for PEN is USD 281.88 over the next 12 months. The maximum analyst target price is USD 340 while the minimum anlayst target price is USD 150.
PEN stock's Price/Earning ratio is 778.91.
Our analysis grades PEN stock's Price / Earning ratio at F. This means that PEN stock's Price/Earning ratio is above 95% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this PEN may be a overvalued for its sector.
The last closing price of PEN's stock was USD 272.32.
The most recent market capitalization for PEN is USD 10.50B.
Based on targets from 14 analysts, the average taret price for PEN is projected at USD 281.88 over the next 12 months.
This means that PEN's stock price may go up by +3.51% over the next 12 months.
We can't find any ETFs which contains Penumbra Inc's stock.
As per our most recent records Penumbra Inc has 4,500 Employees.
Penumbra Inc's registered address is One Penumbra Place, Alameda, CA, United States, 94502.
You can get more information about it from Penumbra Inc's website at https://www.penumbrainc.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PEN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
